Everything below concerns Regulatory status. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-22. Numbers and descriptions here follow the published literature rather than marketing material.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
poly(A) tail A post-transcriptional modification consisting of a chain of repeated adenosine residues, 40–250 nucleotides in length, attached to the 3' end of nearly all mature eukaryotic messenger RNA transcripts (those of histones being a notable exception).
=== Recreational use === Although some studies have reported flupirtine has no addictive properties, there was suggestion that it may possess some miuse potential and liability. There were at least two registered cases of flupirtine misuse. Drug tolerance does not develop in most cases, but has individually occurred. Flupirtine was reported as a novel designer drug in 2025. The effects of flupirtine have been said to be very difficult to describe. They have been reported to include "strong helicopter-like effects at high doses" causing users to have to "walk leaning against a wall", dissociative effects, feelings of euphoria throughout the body, and a very light buzzing sensation. Some have compared it to mephedrone, while others have described the physical bodily sensations as similar to those of MDMA and other entactogens. The drug is said to be able to produce psychosis and mania as adverse effects and to do so more readily than cathinone stimulants. The euphoria produced by flupirtine is said to last 40 to 60 minutes, whereas other effects last all day. The effects are said to convert after 2 hours from stimulant or euphoriant effects into a kind of nootropic effect that affects thinking. The drug is frequently used to enhance the effects of other recreational drugs.
They invented a stochastic corrector model that assumed that replicative templates compete within compartments, and selective values of these compartments depend on the internal composition of templates. Numerical simulations showed that when stochastic effects are taken into account, compartmentalization is sufficient to integrate information dispersed in competitive replicators without the need for hypercycle organization. Moreover, it was shown that compartmentalized hypercycles are more sensitive to the input of deleterious mutations than a simple package of competing genes. Nevertheless, package models do not solve the error threshold problem that originally motivated the hypercycle.
== Implementation == The Carter Center, who was appointed as the independent observer of the agreement's implementations in 2017, stated that 22% of the accords' provisions were put into effect by 2017, and by 2020, that number had only increased to 23%. While the Malian Army was dispatched to Kidal as per the terms of the agreement, the troops never actually patrolled the city. Similarly, CMA fighters were sent to Gao under similar provisions. Part of the reason for the lack of implementation was the need for more willingness by the signatories to honor it. A March 2020 survey showed slightly over eighty percent of Malian civilians had little to no knowledge of the peace agreement. The CMA continued to exercise de facto control over the Kidal region, which the Malian government tolerated as Malian government control of the region would force the government to enact constitutional reforms upending the status quo.
=== Protein complex immunoprecipitation (Co-IP) === Immunoprecipitation of intact protein complexes (i.e. antigen along with any proteins or ligands that are bound to it) is known as co-immunoprecipitation (Co-IP). Co-IP works by selecting an antibody that targets a known protein that is believed to be a member of a larger complex of proteins. By targeting this known member with an antibody it may become possible to pull the entire protein complex out of solution and thereby identify unknown members of the complex. This works when the proteins involved in the complex bind to each other tightly, making it possible to pull multiple members of the complex out of the solution by latching onto one member with an antibody. This concept of pulling protein complexes out of solution is sometimes referred to as a "pull-down". Co-IP is a powerful technique that is used regularly by molecular biologists to analyze protein–protein interactions.
Sources: en.wikipedia.org
== Life == Archerd was always interested in medicine but had neither the discipline nor the money to pursue his interest. In 1940 and 1941, he worked as an assistant at the Camarillo State Mental Hospital in wards where patients were treated with insulin shock therapies. In 1950, he was sentenced to five years of probation for possession of morphine in San Francisco. After another conviction, this parole was revoked. After escaping from a minimum-security prison in Chino, he was rearrested, put in San Quentin Prison, and released again in 1953 on probation. His home was in the Alhambra region of the San Gabriel Valley in Los Angeles County, California.
"Dépouillement des registres de la série V6E des Archives de la ville de Paris, échappés aux incendies de mai 1871" [Examination of the registers in series V6E of the Archives of the City of Paris, which escaped the fires of May 1871] (in French). Archived from the original on February 3, 2016. "Site des Archives départementales des Hauts-de-Seine" [Hauts-de-Seine Departmental Archives website] (in French). Archived from the original on June 14, 2016. "Site des Archives départementales de Seine-Saint-Denis" [Seine-Saint-Denis Departmental Archives website] (in French). Archived from the original on September 14, 2018. "Site des Archives départementales du Val-de-Marne" [Val-de-Marne Departmental Archives website] (in French). Archived from the original on March 18, 2018.
== Taxonomy == The classification of corals has been discussed for millennia, owing to having similarities to both plants and animals. Aristotle's pupil Theophrastus described the red coral, korallion, in his book on stones, implying it was a mineral, but he described it as a deep-sea plant in his Enquiries on Plants, where he also mentions large stony plants that reveal bright flowers when under water in the Gulf of Heroes. Pliny the Elder stated boldly that several sea creatures including sea nettles and sponges "are neither animals nor plants, but are possessed of a third nature (tertia natura)". Petrus Gyllius copied Pliny, introducing the term zoophyta for this third group in his 1535 book On the French and Latin Names of the Fishes of the Marseilles Region; it is popularly but wrongly supposed that Aristotle created the term. Gyllius further noted, following Aristotle, how hard it was to define what was a plant and what was an animal. The Babylonian Talmud refers to coral among a list of types of trees, and the 11th-century French commentator Rashi describes it as "a type of tree (מין עץ) that grows underwater that goes by the (French) name 'coral'." The Persian polymath Al-Biruni (d.1048) classified sponges and corals as animals, arguing that they respond to touch. Nevertheless, people believed corals to be plants until the eighteenth century when William Herschel used a microscope to establish that coral had the characteristic thin cell membranes of an animal.
=== Mechanical === Adhesive materials fill the voids or pores of the surfaces and hold surfaces together by interlocking. Other interlocking phenomena are observed on different length scales. Sewing is an example of two materials forming a large scale mechanical bond, velcro forms one on a medium scale, and some textile adhesives (glue) form one at a small scale.
An international consortium of researchers from 10 countries began sequencing the tomato genome in 2004. A prerelease version of the genome was made available in December 2009. The complete genome for the cultivar Heinz 1706 was published on 31 May 2012 in Nature. The latest reference genome published in 2021 had 799 MB and encodes 34,384 (predicted) proteins, spread over 12 chromosomes. The first commercially available genetically modified food was a tomato called Flavr Savr, which was engineered to have a longer shelf life. It could be vine ripened without compromising shelf life, which was expected to improve the flavor over ethylene-ripened tomatoes. However, it was not firmer than its unmodified parent, to the disappointment of its creators, who originally wanted to create a vine-ripened tomato that could survive machine-picking. The parent variety was also subpar in terms of yields. As a result, the product was not commercially successful, and was sold only until 1997. When the Mesoamericans domesticated tomatoes, they selected for less bitter fruits. This corresponded to the increased activity of a 2-oxoglutarate-dependent dioxygenase called 23DOX (synonym GAME31) during fruit ripening, which converts the bitter and slightly toxic α-tomatine into hydroxytomatine, which is eventually converted into the non-bitter and non-toxic esculeoside A.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.